Evestra Onkologia is proud to obtain funding from the Operational Programme Smart Development for the project entitled “Development of selective treatment of endometriosis based on mesoprogestins”.
The aim of this project is to develop a novel and only- in- class, mesoprogestin – EC313 to treat endometriosis. Although EC313 can be described as a SPRMs, it significantly differs from other representatives of this class. EC313 has been characterized as a mesoprogestin, chemistry compound in which the agonistic and antagonistic activity ratio has been optimized. This project is the business foundation of Evestra Oncology in Poland and serves as the basis for the long-term development of the Evestra Onkologia as a biopharmaceutical company.
The project is co-financed by the European Union from the European Regional Development Fund and the state budget. Total project budget: 18, 706, 957.80 zł.